Chronic liver disease management is a comprehensive approach requiring multi-professional expertise and well-orchestrated healthcare measures thoroughly organized by responsible medical units. Contextually, the corresponding multi-faceted chain of healthcare events is likely to be severely disturbed or even temporarily broken under the force majeure conditions such as global pandemics. Consequently, the chronic liver disease is highly representative for the management of any severe chronic disorder under lasting pandemics with unprecedented numbers of acutely diseased persons who, together with the chronically sick patient cohorts, have to be treated using the given capacity of healthcare systems with their limited resources. Current study aimed at exploring potentially negative impacts of the SARS CoV-2 outbreak on the quality of the advanced chronic liver disease (ACLD) management considering two well-classified parameters, namely, (1) the continuity of the patient registrations and (2) the level of mortality rates, comparing pre-COVID-19 statistics with these under the current pandemic in Slovak Republic. Altogether 1091 registrations to cirrhosis registry (with 60.8% versus 39.2% males to females ratio) were included with a median age of 57 years for patients under consideration. Already within the very first 3 months of the pandemic outbreak in Slovakia (lockdown declared from March 16, 2020, until May 20, 2020), the continuity of the patient registrations has been broken followed by significantly increased ACLD-related death rates. During this period of time, the total number of new registrations decreased by about 60% (15 registrations in 2020 versus 38 in 2018 and 38 in 2019). Corresponding mortality increased by about 52% (23 deaths in 2020 versus 10 in 2018 and 12 in 2019). Based on these results and in line with the framework of 3PM guidelines, the pandemic priority pathways (PPP) are strongly recommended for maintaining tertiary care uninterrupted. For the evidence-based implementation of PPP, creation of predictive algorithms and individualized care strategy tailored to the patient is essential. Resulting classification of measures is summarized as follows:The Green PPP Line is reserved for prioritized (urgent and comprehensive) treatment of patients at highest risk to die from ACLD (tertiary care) as compared to the risk from possible COVID-19 infection.The Orange PPP Line considers patients at middle risk of adverse outcomes from ACLD with re-addressing them to the secondary care. As further deterioration of ACLD is still probable, pro-active management is ascertained with tertiary center serving as the 24/7 telemedicine consultation hub for a secondary facility (on a physician-physician level).The Red PPP Line is related to the patients at low risk to die from ACLD, re-addressing them to the primary care. Since patients with stable chronic liver diseases without advanced fibrosis are at trivial inherent risk, they should be kept out of the healthcare setting as far as possible by the telemedical (patient-nurse or patient- physician) measurements. The assigned priority has to be monitored and re-evaluated individually-in intervals based on the baseline prognostic score such as MELD. The approach is conform with principles of predictive, preventive and personalized medicine (PPPM / 3PM) and demonstrates a potential of great clinical utility for an optimal management of any severe chronic disorder (cardiovascular, neurological and cancer) under lasting pandemics.

5th Department of Internal Medicine Comenius University Faculty of Medicine University Hospital Bratislava Ruzinov Bratislava Slovakia

Central Evidence Department Health Care Surveillance Authority Bratislava Slovakia

Department of Internal Medicine 3Rd Medical Faculty Charles University Thomayer Hospital Prague Prague Czech Republic

Department of Mathematics Faculty of Natural Sciences Matej Bel University Banska Bystrica Slovakia

Department of Science and Research F D Roosevelt Teaching Hospital Banska Bystrica Slovakia

Forensic Medicine and Pathological Anatomy Department Health Care Surveillance Authority Bratislava Slovakia

HEGITO of the Department of Internal Medicine 2 Faculty of Medicine Slovak Medical University F D Roosevelt Teaching Hospital Banska Bystrica Slovakia

PM Research Unit Department of Radiation Oncology University Hospital Medical Faculty Rheinische Friedrich Wilhelms Universität Bonn 53107 Bonn Germany

Predictive Preventive Personalised Medicine Department of Radiation Oncology University Hospital Bonn Rheinische Friedrich Wilhelms Universität Bonn Bonn Germany

Zobrazit více v PubMed

Guzzetta G, Poletti P, Ajelli M, Trentini F, Marziano V, Cereda D, et al. Potential short-term outcome of an uncontrolled COVID-19 epidemic in Lombardy, Italy, February to March 2020. Euro Surveill. 2020;25(12):2000293. doi: 10.2807/1560-7917.ES.2020.25.12.2000293. PubMed DOI PMC

Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med. 2020;382(18):1708–1720. doi: 10.1101/2020.02.06.20020974. PubMed DOI PMC

Grasselli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574–1581. doi: 10.1001/jama.2020.5394. PubMed DOI PMC

Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428–430. doi: 10.1016/S2468-1253(20)30057-1. PubMed DOI PMC

WHO. The World Health Organization declared the SARS-CoV-2 infection (COVID-19), which originated in December 2019 in Wuhan, China, a global pandemic WHO Director-General’s opening remarks at the media briefing on COVID-19. 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-.11-march-2020. Accessed 11 Mar 2020.

Scudellari M. How the pandemic might playout in 2021 and beyond. Nature. 2020;584:22–25. doi: 10.1038/d41586-020-02278-5. PubMed DOI

Kupferschmidt K. Can Europe tame the pandemic’s next wave? Science. 2020;369(6508):1151–1152. doi: 10.1126/science.369.6508.1151. PubMed DOI

WebMD. How scientists predict how many people will get COVID-19. 2020. https://www.webmd.com/lung/news/20200401/how-scientists-predict-how-many-people-will-get-covid-19#1. Accessed 5 May 2020.

Williams R, Jenkins DA, Ashcroft DM, Brown B, Campbell S, Carr MJ, Cheraghi-Sohi S, Kapur N, Thomas O, Webb RT, Peek N. Diagnosis of physical and mental health conditions in primary care during the COVID-19 pandemic: a retrospective cohort study. Lancet Public Health. 2020;5(10):543–550. doi: 10.1016/S2468-2667(20)30201-2. PubMed DOI PMC

Jazieh AR, Akbulut H, Curigliano G, Rogado A, Alsharm AA, Razis ED, Mula-Hussain L, Errihani H, Khattak A, De Guzman RB, Mathias C, Alkaiyat MOF, Jradi H, Rolfo CH, on behalf of the International Research Network on COVID-19 Impact on Cancer Care Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study. JCO Global Oncology. 2020;6:1428–1438. doi: 10.1200/GO.20.00351. PubMed DOI PMC

Radanliev P, De Roure D, Walton R, Van Kleek M, Montalvo RM, Santos O, Maddox L, Cannady S. COVID-19 what have we learned? The rise of social machines and connected devices in pandemic management following the concepts of predictive, preventive and personalized medicine. EPMA J. 2020;11(3):311–332. doi: 10.1007/s13167-020-00218-x. PubMed DOI PMC

Chaari L, Golubnitschaja O. Covid-19 pandemic by the “real-time” monitoring: the Tunisian case and lessons for global epidemics in the context of 3PM strategies. EPMA J. 2020;11(2):1–6. doi: 10.1007/s13167-020-00207-0. PubMed DOI PMC

Ahluwalia P, Ahluwalia M, Vaibhav K, Mondal A, Sahajpal N, Islam S, Fulzele S, Kota V, Dhandapani K, Baban B, Rojiani AM, Kolhe R. Infections of the lung: a predictive, preventive and personalized perspective through the lens of evolution, the emergence of SARS-CoV-2 and its pathogenesis. EPMA J. 2020;13:1–21. doi: 10.1007/s13167-020-00230-1. PubMed DOI PMC

Mao R, Qui Y, He J, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(7):667–678. doi: 10.1016/S2468-1253(20)30160-6. PubMed DOI PMC

Bollipo S, et al. One world, one pandemic, many guidelines: management of liver diseases during COVID-19. Gut. 2020;69(8):1369–1372. doi: 10.1136/gutjnl-2020-321553. PubMed DOI PMC

Lei P, Mi M, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional. multicenter study. Am J Gastroenternol. 2020;115:766–773. doi: 10.14309/ajg.0000000000000620. PubMed DOI PMC

Jothimani D, Venugopal R, Abedin MF, et al. COVID – 19 and Liver. J Hepatol. 2020;73(5):1231–1240. doi: 10.1016/j.jhep.2020.06.006. PubMed DOI PMC

Qi X, Liu Ch, Jiang Z. Multicenter analysis of clinical characteristics and outcome of COVID – 19 patients with liver injury. J Hepatol. 2020;73(2):455–458. doi: 10.1016/j.jhep.2020.04.010. PubMed DOI PMC

Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, Berg T. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. J HEP Rep. 2020;2(3):100113. doi: 10.1016/j.jhepr.2020.100113. PubMed DOI PMC

Tapper EB, Asrani SK. The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care. J Hepatol. 2020;73:441–445. doi: 10.1016/j.jhep.2020.04.005. PubMed DOI PMC

Ivanore M, D’Amrosio R, Soria A, et al. High rate of 30 – day mortality in patients with cirrhosis and COVID – 19. J Hepatol. 2020;73(5):1063–1071. doi: 10.1016/j.jhep.2020.06.001. PubMed DOI PMC

Ferm S, Fisher C, Pakala T. Analysis of gastrointestinal and hepatic manifestations of SARS-CoV-2 infection in 892 patients in Queens, NY. Clin Gastroenterol Hepatol. 2020;18(10):2378–2379. doi: 10.1016/j.cgh.2020.05.049. PubMed DOI PMC

Sultan S, Altayar O, Siddique SM, et al. AGA Institute rapid review of the gastrointestinal and liver manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19. Gastroenterology. 2020;159(1):320–334. doi: 10.1053/j.gastro.2020.05.001. PubMed DOI PMC

Singh S, Khan A. Clinical characteristics and outcomes of COVID-19 among patients with pre-existing liver disease in United States: a Multi-Center Research Network study. Gastroenterology. 2020;159(2):768–771. doi: 10.1053/j.gastro.2020.04.064. PubMed DOI PMC

Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58(3):593–608. doi: 10.1016/j.jhep.2012.12.005. PubMed DOI

Asran SM, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151–171. doi: 10.1016/j.jhep.2018.09.014. PubMed DOI

Národné centrum zdravotníckych informácií (National Health Information Centre -founded by the Ministry of Health of the Slovak Republic). Health Statistics Yearbook of the Slovak Republic 2018. 2019. http://www.nczisk.sk/Documents/rocenky/2018/Zdravotnicka_rocenka_Slovenskej_republiky_2018.pdf. Accessed 6 Nov 2019.

Úrad verejného zdravotníctva Slovenskej republiky (Public Health Authority of the Slovak Republic). COVID-19: the Government of the Slovak Republic took other important measures at an extraordinary meeting. http://www.uvzsr.sk/index.php?option=com_content&view=article&id=4098:covid-19-vlada-sr-prijala-na-mimoriadnom-zasadnuti-alie-doleite-opatrenia&Itemid=153. Accessed 15 Mar 2020.

Serper M, Cubell AW, Deleener ME, Casher TK, Rosenberg DJ, Whitebloom D, et al. Telemedicine in liver disease and beyond: can the COVID-19 crisis lead to action? Hepatology. 2020;72(2):723–728. doi: 10.1002/hep.31276. PubMed DOI PMC

HHS. Notification of enforcement discretion for telehealth remote communications during the COVID-19 nationwide public health emergency. 2020. https://www.hhs.gov/hipaa/for-professionals/special-topics/emergency-preparedness/notification-enforcement-discretion-telehealth/index.html. Accessed 30 Mar 2020.

Skladany L, Koller T, Molcan P, et al. Prognostic usefulness of serum myostatin in advanced chronic liver disease: its relation to gender and correlation with inflammatory status. J Physiol Pharmacol. 2019;70(3):357–368. doi: 10.26402/jpp.2019.3.03. PubMed DOI

Golubnitschaja O, Topolcan O, Kucera R, Costigliola V, EPMA 10th Anniversary of the European Association for Predictive, Preventive and Personalised (3P) Medicine - EPMA World Congress Supplement 2020. EPMA Journal. 2020;11:1–133. doi: 10.1007/s13167-020-00206-1. PubMed DOI PMC

Golubnitschaja O, Baban B, Boniolo G, Wang W, Bubnov R, Kapalla M, et al. Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016. EPMA Journal. 2016;7:23. doi: 10.1186/s13167-016-0072-4. PubMed DOI PMC

R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna; 2020. https://www.R-project.org/. Accessed 10 Oct 2020.

Therneau TM. A package for survival analysis in R. R package version 3.1-12; 2020.  https://CRAN.R-project.org/package=survival. Accessed 28 Sep 2020.

Therneau TM, Grambsch PM. Modeling survival data: extending the cox model. New York: Springer; 2001.

Grady D. The pandemic’s hidden victims: sick or dying, but not from the virus. New York Times 2020. https://www.nytimes.com/2020/04/20/health/treatment-delays-coronavirus.html. Accessed 20 Apr 2020.

Rosenbaum L. The untold toll — the pandemic’s effects on patients without Covid-19. N Engl J Med. 2020;382(24):2368–2371. doi: 10.1056/NEJMms2009984. PubMed DOI

Serper M, Shaked A, Olthoff KM. A local response to COVID – 19 for advanced liver disease: current model of care, challenges and opportunities. J Hepatol. 2020;73:696–739. doi: 10.1016/j.jhep.2020.05.022. PubMed DOI PMC

Becchetti C, Zambelli MF, Pasulo L, COVID-LT group et al. COVID-19 in an international European liver transplant recipient cohort. Gut. 2020;69:1832–1840. doi: 10.1136/gutjnl-2020-321923. PubMed DOI PMC

Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61:1385–1396. doi: 10.1016/j.jhep.2014.08.010. PubMed DOI

Bajaj JS, Garcia-Tsao G, Biggins SW, et al. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut 2020;1–6.10.1136/gutjnl-2020-322118. PubMed PMC

Sarin SK, Choudhury A, Lau GK, et al. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS study (APASL COVID-19 liver injury spectrum study) Hepatol Int. 2020;14:690–700. doi: 10.1007/s12072-020-10072-8. PubMed DOI PMC

Moon AM, Webb GJ, Aloman C, Armstrong MJ, Cargill T, Dhanasekaran R, Genescà J, Gill US, James TW, Jones PD, Marshall A, Mells G, Perumalswami PV, Qi X, Su F, Ufere NN, Barnes E, Barritt AS, Marjot T. High mortality ratesfor SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry. J Hepatol. 2020;73(3):705–708. doi: 10.1016/j.jhep.2020.05.013. PubMed DOI PMC

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3. PubMed DOI PMC

Schmidt ML, Barritt AS, Orman ES, Hayashi PH. Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010. Gastroenterology. 2015;148(5):967–977. doi: 10.1053/j.gastro.2015.01.032. PubMed DOI PMC

Rehm J, Kilian C, Ferreira-Borges C, et al. Alcohol use in times of the COVID 19: implications for monitoring and policy. Drug Alcohol Rev. 2020;39:301–304. doi: 10.1111/dar.13074. PubMed DOI PMC

Clay JM, Parker MO. Alcohol use and misuse during the COVID-19 pandemic: a potential public health crisis? Lancet Public Health. 2020;5(5):e259. doi: 10.1016/S2468-2667(20)30088-8. PubMed DOI PMC

Finlay I, Gilmore I. Covid-19 and alcohol— a dangerous cocktail. BMJ. 2020;369:1987. doi: 10.1136/bmj.m1987. PubMed DOI

Holmes L. Drinking during lockdown: headline findings. 2020. https://alcoholchange.org.uk/blog/2020/COVID-19-drinking-during-lockdown-headlinefindings. Accessed 20 Apr 2020.

Koopman A, Georgiadou E, Kiefer F, Hillemacher T. Did the General Population in Germany Drink More Alcohol during the COVID-19 Pandemic Lockdown? Alcohol Alcohol. 2020;55(6):698–699. doi: 10.1093/alcalc/agaa058. PubMed DOI PMC

Tang LV, Hu Y. Poor clinical outcomes for patients with cancer during the COVID-19 pandemic. Lancet Oncol. 2020;21(7):862–864. doi: 10.1016/S1470-2045(20)30311-9. PubMed DOI PMC

Polak WG, et al. Impact of COVID-19 on liver transplantation in Europe: alert from an early survey of European Liver and Intestine Transplantation Association and European Liver Transplant Registry. Transpl Int. 2020;33(10):1244–1252. doi: 10.1111/tri.13680. PubMed DOI PMC

May T, Floyd TM, Rogers J. Lockdown-type measures look effective against covid-19. BMJ. 2020;370:2743. doi: 10.1136/bmj.m2809. PubMed DOI

Islam N, Sharp SJ, Chowell G, et al. Physical distancing interventions and incidence of coronavirus disease 2019: natural experiment in 149 countries. BMJ. 2020;370:2743. doi: 10.1136/bmj.m2743. PubMed DOI PMC

SECURE Cirrhosis Registry. Surveillance epidemiology of Coronavirus (COVID – 19) under research exclusion. 2020. https://covidcirrhosis.web.unc.edu. Accessed 24 Mar 2020.

Salje H, Kiem CT, Lefrancq N, Courtejoie N, Bosetti P, Pair J. Estimating the burden of SARS-CoV-2 in France. Science. 2020;369(6500):208–211. doi: 10.1126/science.abc3517. PubMed DOI PMC

Markar SR, Clarke J, Kinross J, Pan Surg Collaborative group Practice patterns of diagnostic upper gastrointestinal endoscopy during the initial COVID-19 outbreak in England. Lancet Gastroenterol Hepatol. 2020;5(9):804–805. doi: 10.1016/S2468-1253(20)30236-3. PubMed DOI PMC

Eshraghian A, Taghavi A, Nikeghbalian S, AliMalek-Hosseini S. Reduced rate of hospital admissions for liver- related morbidities during the initial COVID-19 outbreak. Lancet Gastroenterol Hepatol. 2020;5(9):803–804. doi: 10.1016/S2468-1253(20)30207-7. PubMed DOI PMC

Lui RN, Wong SH, Sánchez-Luna SA, et al. Overview of guidance for endoscopy during the coronavirus disease 2019 pandemic. J Gastroenterol Hepatol. 2020;35(5):749–759. doi: 10.1111/jgh.15053. PubMed DOI

Parasa S, Reddy N, Faigel DO, Repici A, Emura F, Sharma P. Global impact of the COVID-19 pandemic on endoscopy: an international survey of 252 centers from 55 countries. Gastroenterology. 2020;159:1579–1581. doi: 10.1053/j.gastro.2020.06.009. PubMed DOI PMC

Vicini E, Galimberti V, Naninato P, Anna Vento AR, Ribeiro Fontana SK, Veronesi P. COVID-19: The European institute of oncology as a “hub” centre for breast cancer surgery during the pandemic in Milan (Lombardy region, northern Italy) - A screenshot of the first month. Eur J Surg Oncol. 2020;46(6):1180–1181. doi: 10.1016/j.ejso.2020.04.026. PubMed DOI PMC

Lui RN, Tang RSY, Chiu FWY. Striving to protect patients and healthcare professionals in endoscopy units during pandemics: from SARS to COVID-19. Gastroenterology 2020. Accepted Date: 1 May 2020. 10.1053/j.gastro.2020.05.002. PubMed PMC

Strnad P, Tacke F, Koch A, Trautwein C. Liver—guardian, modifier and target of sepsis. Nat Rev Gastroenterol Hepatol. 2017;14(1):55–66. doi: 10.1038/nrgastro.2016.168. PubMed DOI

Xiao Y, Pan H, She Q, Wang F, Chen M, Xiao Y, Pan H, She Q, Wang F, Chen M. Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis. Lancet Gastroenterol Hepatol. 2020;5(6):528–529. doi: 10.1016/S2468-1253(20)30080-7. PubMed DOI PMC

AASLD. Covid and the liver. 2020. https://www.aasld.org/about-aasld/covid-19-and-liver. Accessed 23 Mar 2020.

Daniel M. Symptom Shame in the COVID – 19 Era: Battling Our Instincts. Am J Gastroenterol. 2020;115(8):1156–1157. doi: 10.14309/ajg.0000000000000724. PubMed DOI PMC

Colaneri M, Seminari E, Piralla A, Zuccaro V, Filippo AD, Baldanti F, et al. Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy. J Hosp Infect. 2020;105(3):474–476. doi: 10.1016/j.jhin.2020.03.018. PubMed DOI PMC

Gustot T. Quality and reproducibility during the COVID-19 pandemic. J Hepatol Reports. 2020;2(4):100141. doi: 10.1016/j.jhepr.2020.100141. PubMed DOI PMC

Swanton C, Scowcroft H. Protecting „Covid protected” cancer hubs. BMJ. 2020;369:2062. doi: 10.1136/bmj.m2062. PubMed DOI

Hollander JE, Carr BG. Virtually Perfect? Telemedicine for Covid-19. N Engl J Med. 2020;382(18):1679–1681. doi: 10.1056/NEJMp2003539. PubMed DOI

Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–337. doi: 10.1016/S1470-2045(20)30096-6. PubMed DOI PMC

Dinmohamed AD, et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol. 2020;21(6):750–751. doi: 10.1016/S1470-2045(20)30265-5. PubMed DOI PMC

Fix OK, Hameed B, Fontana RJ, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology. 2020;72(1):287–304. doi: 10.1002/hep.31281. PubMed DOI PMC

Colmenero J, Rodríguez Perálvarez M, Salcedo M, et al. Epidemiological pattern, incidence and outcomes of COVID – 19 in liver transplant patients. J Hepatol. 2020 doi: 10.1016/j.jhep.2020.07.040. PubMed DOI PMC

D’Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl. 2020;26(6):832–834. doi: 10.1002/lt.25756. PubMed DOI

Webb GJ, Moon AM, Barnes E, Barritt AS, Marjot T. Determining risk factors for mortality in liver transplant patients with COVID-19. Lancet Gastroenterol Hepatol. 2020;5(7):643–644. doi: 10.1016/S2468-1253(20)30125-4. PubMed DOI PMC

Sharma R, Pinato DJ. Management of hepatocellular cancer in the time of SARS-CoV-2. Liver International. 2020;40(8):1823–1825. doi: 10.1111/liv.14517. PubMed DOI PMC

Ianiro G, Mullish BH, Kelly CR, et al. Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. Lancet Gastroenterol Hepatol. 2020;5(5):430–432. doi: 10.1016/S2468-1253(20)30082-0. PubMed DOI PMC

Green ChG, Quraishi MN, Shabir S, et al. Screening faecal microbiota transplant donors for SARS-CoV-2 by molecular testing of stool is the safest way forward. The Lancet Gastroenterol Hepatol. 2020;5(6):531. doi: 10.1016/S2468-1253(20)30089-3. PubMed DOI PMC

Zhao X, Wang K, Zuo P, Liu Y, Zhang M, Xie S, Zhang H, Chen X, Liu C. Early decrease in blood platelet count is associated with poor prognosis in COVID-19 patients-indications for predictive, preventive, and personalized medical approach. EPMA J. 2020;11(2):1–7. doi: 10.1007/s13167-020-00208-z. PubMed DOI PMC

Lee WM. Introduction to the Revised American Association for the Study of Liver Diseases Position Paper on Acute Liver Failure 2011. In: AASLD position paper. 2012. https://www.aasld.org/sites/default/files/2019-06/AcuteLiverFailureUpdate201journalformat1.pdf. Accessed 5 Nov 2011. PubMed PMC

EASL EASL clinical practical guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047–1081. doi: 10.1016/j.jhep.2016.12.003. PubMed DOI

Hernaez R, Sola E, Moreau R, Gines P. Acute-on-chronic liver failure: an update Gut. 2017;66:541–553. doi: 10.1136/gutjnl-2016-312670. PubMed DOI PMC

Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365:1790–1800. doi: 10.1056/NEJMoa1105703. PubMed DOI

Weeks SR, Sun Z, McCaul ME, Zhu H, Anders RA, Philosophe B, et al. Liver transplantation for severe alcoholic hepatitis, updated lessons from the world’s largest series. J Am Coll Surg. 2018;226(4):549–557. doi: 10.1016/j.jamcollsurg.2017.12.044. PubMed DOI

Targeting phytoprotection in the COVID-19-induced lung damage and associated systemic effects-the evidence-based 3PM proposition to mitigate individual risks